{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:08:55Z","timestamp":1788804535451,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Research Ward Excellence Program","award":["BRWEP2024W054070100"],"award-info":[{"award-number":["BRWEP2024W054070100"]}]},{"name":"Interdepartmental Clinical Research Project of Peking University First Hospital","award":["2023IR27"],"award-info":[{"award-number":["2023IR27"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370773"],"award-info":[{"award-number":["82370773"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Indications for repeat biopsy after an initial negative prostate biopsy remain poorly defined. Therefore, this study aimed to investigate the effectiveness of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) scoring system as a guide for repeat biopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed patients who underwent repeat prostate biopsy and had bpMRI performed before both biopsies between 2013 and 2024. The association of clinically significant prostate cancer (csPCa) detection with initial Prostate Imaging Reporting and Data System (PI-RADS) and PRECISE scores was analyzed. The predictive effects of prostate-specific antigen density before repeat biopsy (re-PSAD) and PSA velocity (PSAV) on csPCa were assessed in patients progressing to or maintaining re-PI-RADS 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>104 individuals were included with a median follow-up period of 28.58 months and a PSAV of 0.90\u2009ng\/mL\/year (interquartile range (IQR), \u22120.17 to 2.57\u2009ng\/mL\/year). The csPCa detection rate at repeat biopsy was 24.0%. 42 participants (40.4%) had PRECISE scores of 4\u20135, 43 (41.3%) had scores of 3, and 19 (18.3%) had scores of 1\u20132. A higher PRECISE score corresponds to a higher csPCa detection rate, with csPCa diagnosed in 52.4% of patients with PRECISE scores of 4\u20135. In subgroup analyses, re-PSAD and PSAV avoided 65.4% and 53.8% of repeat biopsies, respectively, and would have caused 5.9% and 0.00% of missed csPCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PRECISE may be useful for guiding repeat biopsy decisions and may provide incremental value for predicting csPCa when interpreted together with PI-RADS. Additionally, PSAD and PSAV can assist in screening for repeat biopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:bold>\n                              <jats:italic>Question<\/jats:italic>\n                            <\/jats:bold>\n                            Indications for repeat prostate biopsy after an initial negative result remain poorly defined. Can sequential MRI PRECISE scoring help inform repeat biopsy decisions?\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:bold>\n                              <jats:italic>Findings<\/jats:italic>\n                            <\/jats:bold>\n                            In our retrospective cohort, PRECISE 1\u20132 yielded no clinically significant cancer, while PRECISE 4\u20135 showed a 52.4% detection rate. PSA parameters aided equivocal cases.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:bold>\n                              <jats:italic>Critical relevance statement<\/jats:italic>\n                            <\/jats:bold>\n                            This study evaluates sequential MRI PRECISE scoring, suggesting its potential to help reduce unnecessary repeat biopsies for regressing lesions while identifying high-risk progressing abnormalities.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13244-026-02373-7","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:52:46Z","timestamp":1788803566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the biopsy-negative prostate lesions based on sequential biparametric prostate magnetic resonance imaging: Can PRECISE be used to guide repeat biopsy?"],"prefix":"10.1186","volume":"17","author":[{"given":"Yuxuan","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6711-6601","authenticated-orcid":false,"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2373_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: Screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163","journal-title":"Eur Urol"},{"key":"2373_CR2","doi-asserted-by":"publisher","first-page":"E293","DOI":"10.5489\/cuaj.1248","volume":"7","author":"EC Serefoglu","year":"2013","unstructured":"Serefoglu EC, Altinova S, Ugras NS, Akincioglu E, Asil E, Balbay MD (2013) How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer? Can Urol Assoc J 7:E293\u2013E298","journal-title":"Can Urol Assoc J"},{"key":"2373_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.eururo.2022.07.025","volume":"82","author":"N Grivas","year":"2022","unstructured":"Grivas N, Lardas M, Espin\u00f3s EL et al (2022) Prostate cancer detection percentages of repeat biopsy in patients with positive multiparametric magnetic resonance imaging (Prostate Imaging Reporting and Data System\/Likert 3-5) and negative initial biopsy. A mini systematic review. Eur Urol 82:452\u2013457","journal-title":"Eur Urol"},{"key":"2373_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eururo.2019.06.023","volume":"77","author":"FH Drost","year":"2020","unstructured":"Drost FH, Osses D, Nieboer D et al (2020) Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis. Eur Urol 77:78\u201394","journal-title":"Eur Urol"},{"key":"2373_CR5","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815\u2013822","journal-title":"Lancet"},{"key":"2373_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2024.09.035","volume":"87","author":"JJ Twilt","year":"2025","unstructured":"Twilt JJ, Saha A, Bosma JS et al (2025) Evaluating biparametric versus multiparametric magnetic resonance imaging for diagnosing clinically significant prostate cancer: an international, paired, noninferiority, confirmatory observer study. Eur Urol 87:240\u2013250","journal-title":"Eur Urol"},{"key":"2373_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109350","volume":"132","author":"C Christophe","year":"2020","unstructured":"Christophe C, Montagne S, Bourrelier S et al (2020) Prostate cancer local staging using biparametric MRI: assessment and comparison with multiparametric MRI. Eur J Radiol 132:109350","journal-title":"Eur J Radiol"},{"key":"2373_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2023.111186","volume":"169","author":"I Rehman","year":"2023","unstructured":"Rehman I, Pang E, Harris AC, Chang SD (2023) Bi-parametric prostate MRI with a recall system for contrast enhanced imaging: improving accessibility while maintaining quality. Eur J Radiol 169:111186","journal-title":"Eur J Radiol"},{"key":"2373_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.euo.2023.01.003","volume":"6","author":"CM Moore","year":"2023","unstructured":"Moore CM, King LE, Withington J et al (2023) Best current practice and research priorities in active surveillance for prostate cancer\u2014a report of a Movember international consensus meeting. Eur Urol Oncol 6:160\u2013182","journal-title":"Eur Urol Oncol"},{"key":"2373_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.eururo.2021.12.007","volume":"81","author":"PM Willemse","year":"2022","unstructured":"Willemse PM, Davis NF, Grivas N et al (2022) Systematic review of active surveillance for clinically localised prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and surveillance repeat biopsy strategy. Eur Urol 81:337\u2013346","journal-title":"Eur Urol"},{"key":"2373_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1001\/jamaoncol.2024.5497","volume":"11","author":"CA Hamm","year":"2025","unstructured":"Hamm CA, Asbach P, P\u00f6hlmann A et al (2025) Oncological safety of MRI-informed biopsy decision-making in men with suspected prostate cancer. JAMA Oncol 11:145\u2013153","journal-title":"JAMA Oncol"},{"key":"2373_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2. Eur Urol 76:340\u2013351","journal-title":"Eur Urol"},{"key":"2373_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","volume":"21","author":"KA Moses","year":"2023","unstructured":"Moses KA, Sprenkle PC, Bahler C et al (2023) NCCN Guidelines\u00ae Insights: Prostate cancer early detection, version 1.2023. J Natl Compr Canc Netw 21:236\u2013246","journal-title":"J Natl Compr Canc Netw"},{"key":"2373_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.euros.2023.08.006","volume":"56","author":"J Aerts","year":"2023","unstructured":"Aerts J, Hendrickx S, Berquin C et al (2023) Clinical application of the prostate cancer radiological estimation of change in sequential evaluation score for reporting magnetic resonance imaging in men on active surveillance for prostate cancer. Eur Urol Open Sci 56:39\u201346","journal-title":"Eur Urol Open Sci"},{"key":"2373_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2214\/AJR.23.29518","volume":"221","author":"N Sanmugalingam","year":"2023","unstructured":"Sanmugalingam N, Sushentsev N, Lee KL et al (2023) The PRECISE recommendations for prostate MRI in patients on active surveillance for prostate cancer: a critical review. AJR Am J Roentgenol 221:649\u2013660","journal-title":"AJR Am J Roentgenol"},{"key":"2373_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","volume":"86","author":"C Englman","year":"2024","unstructured":"Englman C, Maffei D, Allen C et al (2024) PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer. Eur Urol 86:240\u2013255","journal-title":"Eur Urol"},{"key":"2373_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/MOU.0000000000000397","volume":"27","author":"IG Schoots","year":"2017","unstructured":"Schoots IG, Moore CM, Rouvi\u00e8re O (2017) Role of MRI in low-risk prostate cancer: finding the wolf in sheep\u2019s clothing or the sheep in wolf\u2019s clothing? Curr Opin Urol 27:238\u2013245","journal-title":"Curr Opin Urol"},{"key":"2373_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.urology.2023.07.019","volume":"180","author":"Y Bhanji","year":"2023","unstructured":"Bhanji Y, Mamawala M, de la Calle CM et al (2023) Prostate cancer radiological estimation of change in sequential evaluation (PRECISE) magnetic resonance imaging scoring to predict clinical outcomes in active surveillance for grade group 1 prostate cancer. Urology 180:194\u2013199","journal-title":"Urology"},{"key":"2373_CR19","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1007\/s00330-020-07336-0","volume":"31","author":"I Caglic","year":"2021","unstructured":"Caglic I, Sushentsev N, Gnanapragasam VJ et al (2021) MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. Eur Radiol 31:2696\u20132705","journal-title":"Eur Radiol"},{"key":"2373_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.5489\/cuaj.7843","volume":"16","author":"E Becher","year":"2022","unstructured":"Becher E, Wysock JS, Taneja SS, Huang WC, Lepor H (2022) A prospective study of cancer detection rates following early repeat imaging and biopsy of PI-RADS 4 and 5 regions of interest exhibiting no clinically significant prostate cancer on prior biopsy. Can Urol Assoc J 16:418\u2013422","journal-title":"Can Urol Assoc J"},{"key":"2373_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/JU.0000000000001424","volume":"205","author":"X Meng","year":"2021","unstructured":"Meng X, Chao B, Chen F, Huang R, Taneja SS, Deng F-M (2021) Followup of men with PI-RADS\u2122 4 or 5 abnormality on prostate magnetic resonance imaging and nonmalignant pathological findings on initial targeted prostate biopsy. J Urol 205:748\u2013754","journal-title":"J Urol"},{"key":"2373_CR22","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.euf.2023.03.011","volume":"9","author":"V Stavrinides","year":"2023","unstructured":"Stavrinides V, Eksi E, Finn R et al (2023) Magnetic resonance imaging follow-up of targeted biopsy\u2013negative prostate lesions. Eur Urol Focus 9:781\u2013787","journal-title":"Eur Urol Focus"},{"key":"2373_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.juro.2017.03.130","volume":"198","author":"FA Distler","year":"2017","unstructured":"Distler FA, Radtke JP, Bonekamp D et al (2017) The value of PSA density in combination with PI-RADS\u2122 for the accuracy of prostate cancer prediction. J Urol 198:575\u2013582","journal-title":"J Urol"},{"key":"2373_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clinimag.2022.09.002","volume":"92","author":"O Kamal","year":"2022","unstructured":"Kamal O, Comerford J, Foster BR, Young DJ, Amling C, Coakley FV (2022) Intermediate-term oncological outcomes after a negative endorectal coil multiparametric MRI of the prostate in patients without biopsy proven prostate cancer. Clin Imaging 92:112\u2013116","journal-title":"Clin Imaging"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-026-02373-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:52:47Z","timestamp":1788803567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13244-026-02373-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2373"],"URL":"https:\/\/doi.org\/10.1186\/s13244-026-02373-7","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Peking University First Hospital (Approval No. 2023YAN272-002). As a retrospective analysis utilizing previously collected data without any additional interventions, the requirement for informed consent was waived by the committee. All data were handled in accordance with the Declaration of Helsinki, ensuring participant privacy and confidentiality.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors of this paper were aware of and agreed to the publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of this article.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"225"}}